Immunotherapy and targeted therapy before surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (serplulimab and trastuzumab rezetecan) given before surgery to shrink tumors in people with early-stage triple-negative breast cancer. The goal is to see if this treatment helps remove more cancer cells before the main surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 years.
- You have early-stage triple-negative breast cancer that has not been treated yet.
- Your tumor is at least a certain size and may have spread to nearby lymph nodes (stage T1cN1-2 or T2-4N0-2).
- You are in good general health (ECOG score 0 or 1), meaning you can do most daily activities.
- Your blood counts, liver, kidney, and heart function are within normal ranges.
- You must provide a tumor sample (from a previous biopsy or a new one) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether a combination of targeted therapies and hormone therapy can shrink triple-positive breast cancer before surgery. It is for women with stage II or III breast cancer that has not yet been treated.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
This trial tests two drugs given before surgery to treat early-stage triple-negative breast cancer that is PD-L1 positive. The goal is to see if the combination can shrink the tumor and improve outcomes.
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.